InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.018 -0.01 (-35.71%)+
Announcement
Release
17 Apr 2026 10:23AM
Price at Release
$0.028
Full Release
download
Summary
Atomo Diagnostics Limited responded to an ASX Aware Letter concerning its recent announcements. The company confirmed that information disclosed was material and had the potential to affect its securities' price. The trading halt was enacted to update the market on the FDA's response to a CLIA waiver application, significantly impacting AT1's Pascal cassettes supplied to Lumos Diagnostics. AT1 believes it adhered to continuous disclosure obligations with careful consideration for confidentiality and market sensitivity, particularly in its capital raising of approximately $4 million through a placement and Share Purchase Plan. The disclosures were timed to maintain market integrity while ensuring compliance with ASX Listing Rules.
Key Points
  • Atomo Diagnostics Limited is responding to an ASX Aware Letter regarding its recent market announcements.
  • AT1 confirmed that the Announcement contained material information that could affect its securities' price.
  • The trading halt was requested to provide an update on the FDA response to a CLIA waiver application relevant to AT1's business.
  • AT1 is the exclusive licensor and manufacturer of Pascal cassettes for Lumos Diagnostics, which impacted by the FDA CLIA waiver.
  • The company believes it complied with continuous disclosure obligations, timing its disclosures to ensure the market was informed.
  • AT1 raised approximately $4 million through a placement and Share Purchase Plan following the Announcement.
  • The company considers its actions and timing of disclosures consistent with ASX Listing Rules, particularly concerning confidentiality and market sensitivity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.